News from us and our partners

Tags

Topics

0 results

News
20 May, 2026
HAYA Therapeutics doses first cohort in Phase 1 trial
News
18 May, 2026
Tulyp Medical appoints Steve Motes as CEO
News
18 May, 2026
Baxfendy approved in the US for hypertension
News
18 May, 2026
Galvanize Therapeutics Receives FDA Clearance for Aliya EX Generator, Expanding its Aliya Pulsed Electric Field Portfolio for Surgical Ablation of Soft Tissue
News
18 May, 2026
Sensorion appoints Fred Chereau as CEO
News
13 May, 2026
Sitryx First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
News
13 May, 2026
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
News
11 May, 2026
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
News
7 May, 2026
Prometheus Materials Announces Strategic Partnership with Green Stream Algae to Scale Microalgae-Based Low-Carbon Cement
News
6 May, 2026
Hemab Therapeutics closes $347M Nasdaq IPO
News
6 May, 2026
CellCentric raises $220M Series D for inobrodib trials
News
6 May, 2026
Signadori Bio raises €11M seed to advance tumour platform
News
5 May, 2026
NanoPhoria Awarded Second-Place Prize in INNLIFES’ “I Protagonisti Dell’innovazione 2026” Contest
News
5 May, 2026
Arzeda and KENT Specialty Milling Announce Strategic Product Development Collaboration
News
30 April, 2026
Hemab Therapeutics prices IPO at $18 per share
News
23 April, 2026
Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes

HAYA Therapeutics doses first cohort in Phase 1 trial

Tulyp Medical appoints Steve Motes as CEO

Baxfendy approved in the US for hypertension

Galvanize Therapeutics Receives FDA Clearance for Aliya EX Generator, Expanding its Aliya Pulsed Electric Field Portfolio for Surgical Ablation of Soft Tissue

Sensorion appoints Fred Chereau as CEO

Sitryx First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026

Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Prometheus Materials Announces Strategic Partnership with Green Stream Algae to Scale Microalgae-Based Low-Carbon Cement

Hemab Therapeutics closes $347M Nasdaq IPO

CellCentric raises $220M Series D for inobrodib trials

Signadori Bio raises €11M seed to advance tumour platform

NanoPhoria Awarded Second-Place Prize in INNLIFES’ “I Protagonisti Dell’innovazione 2026” Contest

Arzeda and KENT Specialty Milling Announce Strategic Product Development Collaboration

Hemab Therapeutics prices IPO at $18 per share

Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes